- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02700009
Computer-assisted Cognitive-Behavior Therapy for Depression in Primary Care
Dissemination of Computer-assisted Cognitive-behavior Therapy for Depression in Primary Care
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Computer-assisted cognitive-behavior therapy (CCBT) for depression in primary care will be evaluated in a trial with 320 patients randomly assigned to CCBT or treatment as usual (TAU). The study will disseminate a therapy method found to be effective in psychiatric settings into primary care - a setting where there have been significant problems in delivery of adequate, evidence-based treatment for depression. The study will include a high percentage of disadvantaged patients - a population that has been largely ignored in previous research in CCBT. There have been no previous studies of CCBT for depression in primary care that have enrolled large numbers of disadvantaged patients. The form of CCBT used in this study is designed to increase access to effective therapy, provide a cost-effective method, and be a sustainable model for wide-spread use in primary care.
In order to deliver therapy in a practical manner that can be replicated in other primary care practices, patients with significant symptoms of depression will receive treatment with an empirically supported computer program that builds cognitive-behavior therapy skills. Support for CCBT will be provided by telephone and/or e-mail contact with a care coordinator instead of the face-to-face treatment with a cognitive-behavior therapist that has been a part of CCBT delivery in mental health settings. Novel features of this treatment program include: 1) fully detailed and replicable method for integrating clinician support with CCBT in primary care; 2) delivery of CCBT to a population with high percentage of disadvantaged patients; 3) integration of CCBT into the primary care delivery model; 4) highly interactive, multimedia computer program with adaptations for persons who may have lower levels of education or computer experience; 5) advanced cost-benefit analysis including data on actual health care utilization and costs; 6) exploration of moderators and predictors of treatment outcome.
Outcome will be assessed by measuring CCBT completion rate, comprehension of CBT concepts, and satisfaction with treatment; in addition to ratings of depressive symptoms, negative thoughts, and quality of life. The cost-effectiveness analysis and exploration of possible predictors of outcome should help clinicians, health care organizations, and others plan further dissemination of CCBT in primary care.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville, School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient Health Questionnaire score of 10 or above
- Age 18 or above
Exclusion Criteria:
- Refusal to provide informed consent
- Inability to read English text on computer screen
- Significant suicidal thoughts, intent, plan, or behavior reported on Columbia Suicide Severity Rating Scale
- Severe or poorly controlled medical disorders that would interfere with participation in CCBT (e.g., liver failure, terminal cancer)
- Dementia or other organic brain disorders that would prevent participation in CCBT
- Diagnosis of any psychotic disorder or bipolar disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Computer-assisted CBT (CCBT)
12 weeks of CCBT for depression
|
Computer-assisted psychotherapy for depression using a computer program plus clinician support
|
|
Active Comparator: Treatment as Usual (TAU)
Treatment as usual by primary care physicians
|
Ordinary treatment for depression in primary care setting
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Health Questionnaire - 9
Time Frame: Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment period ends
|
Self-report scale for depression
|
Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment period ends
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Automatic Thoughts Questionnaire
Time Frame: Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment period ends
|
Self-report measure of negative cognitions
|
Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment period ends
|
|
Quality of Life Enjoyment and Satisfaction Questionnaire
Time Frame: Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment period ends
|
Self-report measure of quality of life
|
Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment period ends
|
|
Client Service Receipt Inventory
Time Frame: Change from baseline after 12 weeks of treatment and 3 and 6 months after 12-week treatment ends
|
Record of medical and related services
|
Change from baseline after 12 weeks of treatment and 3 and 6 months after 12-week treatment ends
|
|
Quality of Well Being Scale
Time Frame: Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment periods ends
|
Self-report measure of well-being
|
Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment periods ends
|
|
Patient Attitudes and Expectations Scale
Time Frame: Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment periods ends
|
Assessment of patient attitudes toward treatment
|
Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment periods ends
|
|
Generalized Anxiety Disorder - 7
Time Frame: Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment period ends
|
Self-report measure of anxiety
|
Change from baseline after 12 weeks of treatment and 3 and 6 months after the 12-week treatment period ends
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jesse Wright, M.D., Ph.D., University of Louisville
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15.0640
- R18HS024047 (U.S. AHRQ Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.